{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:32:07Z","timestamp":1785763927132,"version":"3.56.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009510","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T00:00:00Z","timestamp":1359590400000}}],"reference-count":81,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009510.pub2","type":"journal-article","created":{"date-parts":[[2013,1,29]],"date-time":"2013-01-29T13:39:27Z","timestamp":1359466767000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion"],"prefix":"10.1002","author":[{"given":"Danny","family":"Mitry","sequence":"first","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust; City Road London UK EC1V 2PD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catey","family":"Bunce","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust; Research and Development Department; City Road London UK EC1V 2PD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Charteris","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust; City Road London UK EC1V 2PD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,31]]},"reference":[{"issue":"8","key":"10.1002\/14651858.CD009510.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD009510.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/IAE.0b013e318195ca65","article-title":"Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion","volume":"29","author":"Russo","year":"2009","journal-title":"Retina"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/mt.2008.10","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator","volume":"16","author":"Campochiaro","year":"2008","journal-title":"Molecular Therapy"},{"issue":"12","key":"10.1002\/14651858.CD009510.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.ophtha.2010.03.060","article-title":"Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.5301\/ejo.5000085","article-title":"Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion","volume":"22","author":"Donati","year":"2012","journal-title":"European Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009510.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00417-010-1440-8","article-title":"Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1)","volume":"249","author":"Moradian","year":"2011","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD009510.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ajo.2009.08.005","article-title":"Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion","volume":"149","author":"Wroblewski","year":"2010","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD009510.pub2-BIB0009|cit9","unstructured":"EUCTR2010-023900-29-GB A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of ozurdex\u00ae versus lucentis\u00ae in patients with branch retinal vein occlusion clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2010-023900-29"},{"key":"10.1002\/14651858.CD009510.pub2-BIB0010|cit10","unstructured":"NCT01189526 A randomized trial comparing intravitreal ranibizumab and macular laser photocoagulation for the treatment of macular edema following branch retinal vein occlusion clinicaltrials.gov\/ct2\/show\/NCT01189526"},{"key":"10.1002\/14651858.CD009510.pub2-BIB0011|cit11","unstructured":"NCT01396057 A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of ranibizumab intravitreal injections versus dexamethasone intravitreal implant in patients with visual impairment due to macular edema following branch retinal vein occlusion (BRVO) clinicaltrials.gov\/ct2\/show\/NCT01396057"},{"key":"10.1002\/14651858.CD009510.pub2-BIB0012|cit12","unstructured":"NCT01521559 Study to assess the clinical efficacy and safety of VEGF trap-eye (intravitreal aflibercept injection [IAI]), also commercially known as EYLEA\u2122 in patients with branch retinal vein occlusion (BRVO) clinicaltrials.gov\/ct2\/show\/NCT01521559"},{"key":"10.1002\/14651858.CD009510.pub2-BIB0013|cit13","unstructured":"NCT01635803 Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with retinal vein occlusions (the BRVO study) clinicaltrials.gov\/ct2\/show\/NCT01635803"},{"key":"10.1002\/14651858.CD009510.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2415-8-18","article-title":"Treatment of branch retinal vein occlusion induced macular edema with bevacizumab","volume":"8","author":"Abegg","year":"2008","journal-title":"BMC Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009510.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3129\/i09-040","article-title":"The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion","volume":"44","author":"Ahmadi","year":"2009","journal-title":"Canadian Journal of Ophthalmology"},{"issue":"23","key":"10.1002\/14651858.CD009510.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","article-title":"Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins","volume":"92","author":"Aiello","year":"1995","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"10.1002\/14651858.CD009510.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1001\/archopht.1995.01100120068012","article-title":"Hypoxic regulation of vascular endothelial growth factor in retinal cells","volume":"113","author":"Aiello","year":"1995","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2007.135913","article-title":"Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire","volume":"94","author":"Awdeh","year":"2010","journal-title":"British Journal of Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD009510.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/archopht.120.12.1644","article-title":"Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion","volume":"120","author":"Boyd","year":"2002","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0002-9394(84)90316-7","article-title":"Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group","volume":"98","author":"Anonymous","year":"1984","journal-title":"American Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1089\/jop.2007.0012","article-title":"Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema","volume":"23","author":"Byeon","year":"2007","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"7","key":"10.1002\/14651858.CD009510.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00417-010-1320-2","article-title":"Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion","volume":"248","author":"Byun","year":"2010","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD009510.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD009510.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3109\/02713683.2010.496540","article-title":"A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion","volume":"35","author":"Cekic","year":"2010","journal-title":"Current Eye Research"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub2-BIB0025|cit25","first-page":"424","article-title":"Treatment of branch retinal vein occlusion induced macular edema in treatment-naive cases with a single intravitreal triamcinolone or bevacizumab injection","volume":"33","author":"Chen","year":"2010","journal-title":"Chang Gung Medical Journal"},{"issue":"11","key":"10.1002\/14651858.CD009510.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1038\/eye.2009.230","article-title":"Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion","volume":"23","author":"Cheng","year":"2009","journal-title":"Eye"},{"issue":"9","key":"10.1002\/14651858.CD009510.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00417-008-0866-8","article-title":"Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion","volume":"246","author":"Chung","year":"2008","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"key":"10.1002\/14651858.CD009510.pub2-BIB0028|cit28","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bjo.66.3.161","article-title":"Retinal vein occlusion and the prevalence of lipoprotein abnormalities","volume":"66","author":"Dodson","year":"1982","journal-title":"British Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD009510.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/eye.1992.13","article-title":"Diabetes mellitus and retinal vein occlusion in patients of Asian, West Indian and white European origin","volume":"6","author":"Dodson","year":"1992","journal-title":"Eye"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0002-9394(14)71345-5","article-title":"Risk factors for branch retinal vein occlusion. The Eye Disease Case-Control Study Group","volume":"116","author":"Anonymous","year":"1993","journal-title":"American Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.survophthal.2010.11.006","article-title":"Retinal vein occlusion: beyond the acute event","volume":"56","author":"Ehlers","year":"2011","journal-title":"Survey of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD009510.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"issue":"8","key":"10.1002\/14651858.CD009510.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/bjo.2009.173732","article-title":"Results of bevacizumab as the primary treatment for retinal vein occlusions","volume":"94","author":"Figueroa","year":"2010","journal-title":"British Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD009510.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/archopht.1982.01030040110020","article-title":"Histopathologic study of nine branch retinal vein occlusions","volume":"100","author":"Frangieh","year":"1982","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1167\/iovs.08-2510","article-title":"Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab","volume":"50","author":"Funk","year":"2009","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub2-BIB0037|cit37","first-page":"455","article-title":"Ranibizumab: in macular oedema following retinal vein occlusion","volume":"71","author":"Garnock-Jones","year":"2011","journal-title":"Drugs"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0161-6420(96)30653-2","article-title":"Prognostic factors for retinal vein occlusion: prospective study of 175 cases","volume":"103","author":"Glacet-Bernard","year":"1996","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009510.pub2-BIB0039|cit39","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"27","key":"10.1002\/14651858.CD009510.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD009510.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/IAE.0b013e3181aa8dfe","article-title":"Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion","volume":"29","author":"Gregori","year":"2009","journal-title":"Retina"},{"issue":"9","key":"10.1002\/14651858.CD009510.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/sj.eye.6703040","article-title":"Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion","volume":"22","author":"Gunduz","year":"2008","journal-title":"Eye"},{"issue":"6","key":"10.1002\/14651858.CD009510.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD009510.pub2-BIB0044|cit44","first-page":"1013","article-title":"Effect of repeated intravitreal bevacizumab injections for secondary macular edema of branch retinal vein occlusion","volume":"114","author":"Hara","year":"2010","journal-title":"Nihon Ganka Gakkai Zasshi"},{"key":"10.1002\/14651858.CD009510.pub2-BIB0045|cit45","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"12","key":"10.1002\/14651858.CD009510.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00417-009-1151-1","article-title":"Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion","volume":"247","author":"Hoeh","year":"2009","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"22","key":"10.1002\/14651858.CD009510.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.3760\/cma.j.issn.0366-6999.2009.22.004","article-title":"Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study","volume":"122","author":"Hou","year":"2009","journal-title":"Chinese Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD009510.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/jop.2009.0090","article-title":"Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion","volume":"26","author":"Hung","year":"2010","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD009510.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00417-008-0916-2","article-title":"One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion","volume":"247","author":"Jaissle","year":"2009","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009510.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00417-010-1470-2","article-title":"Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion","volume":"249","author":"Jaissle","year":"2011","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"key":"10.1002\/14651858.CD009510.pub2-BIB0051|cit51","first-page":"133","article-title":"The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study","volume":"98","author":"Klein","year":"2000","journal-title":"Transactions of the American Ophthalmological Society"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archopht.126.4.513","article-title":"The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study","volume":"126","author":"Klein","year":"2008","journal-title":"Archives of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD009510.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/IAE.0b013e3181aa8e20","article-title":"Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis","volume":"29","author":"Kondo","year":"2009","journal-title":"Retina"},{"issue":"9","key":"10.1002\/14651858.CD009510.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.clinthera.2007.09.008","article-title":"Ranibizumab for the treatment of neovascular age-related macular degeneration: a review","volume":"29","author":"Kourlas","year":"2007","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/bjo.2007.123513","article-title":"Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion","volume":"92","author":"Kreutzer","year":"2008","journal-title":"British Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/bjo.2007.127282","article-title":"Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study","volume":"92","author":"Kriechbaum","year":"2008","journal-title":"British Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD009510.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ophtha.2007.01.010","article-title":"Interventions for branch retinal vein occlusion: an evidence-based systematic review","volume":"114","author":"McIntosh","year":"2007","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.sjopt.2010.03.004","article-title":"Early Avastin management in acute retinal vein occlusion","volume":"24","author":"Mehany","year":"2010","journal-title":"Saudi Journal of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD009510.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/archopht.1996.01100140443012","article-title":"Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study","volume":"114","author":"Mitchell","year":"1996","journal-title":"Archives of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD009510.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1185\/03007995.2011.585394","article-title":"A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab","volume":"27","author":"Mitchell","year":"2011","journal-title":"Current Medical Research and Opinion"},{"issue":"3","key":"10.1002\/14651858.CD009510.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00417-004-1087-4","article-title":"Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion","volume":"244","author":"Noma","year":"2006","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1006\/exer.1996.0239","article-title":"Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates","volume":"64","author":"Ozaki","year":"1997","journal-title":"Experimental Eye Research"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ajo.2006.12.037","article-title":"Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion","volume":"143","author":"Pai","year":"2007","journal-title":"American Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD009510.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/bjo.2009.174060","article-title":"Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up","volume":"95","author":"Pece","year":"2011","journal-title":"British Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bjo.2008.141085","article-title":"Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial","volume":"93","author":"Prager","year":"2009","journal-title":"British Journal of Ophthalmology"},{"issue":"20","key":"10.1002\/14651858.CD009510.pub2-BIB0066|cit66","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IAE.0b013e318030e77e","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion","volume":"27","author":"Rabena","year":"2007","journal-title":"Retina"},{"issue":"2","key":"10.1002\/14651858.CD009510.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/02713680701851902","article-title":"Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities","volume":"33","author":"Rehak","year":"2008","journal-title":"Current Eye Research"},{"issue":"2","key":"10.1002\/14651858.CD009510.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000183844","article-title":"Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion","volume":"223","author":"Rensch","year":"2009","journal-title":"Ophthalmologica"},{"key":"10.1002\/14651858.CD009510.pub2-BIB0070|cit70","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan). Version 5.1 2011"},{"issue":"6","key":"10.1002\/14651858.CD009510.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.ophtha.2010.01.058","article-title":"Natural history of branch retinal vein occlusion: an evidence-based systematic review","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009510.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1002\/14651858.CD009510.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD009510.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/IAE.0b013e3181cd4894","article-title":"Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study","volume":"30","author":"Rouvas","year":"2010","journal-title":"Retina"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00347-007-1509-x","article-title":"Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion","volume":"104","author":"Schaal","year":"2007","journal-title":"Ophthalmologe"},{"issue":"9","key":"10.1002\/14651858.CD009510.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archophthalmol.2009.233","article-title":"A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6","volume":"127","author":"Scott","year":"2009","journal-title":"Archives of Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD009510.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/bjo.60.12.810","article-title":"New vessel formation in retinal branch vein occlusion","volume":"60","author":"Shilling","year":"1976","journal-title":"British Journal of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD009510.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00417-007-0569-6","article-title":"Bevacizumab in retinal vein occlusion-results of a prospective case series","volume":"245","author":"Stahl","year":"2007","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009510.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ophtha.2004.10.039","article-title":"Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies","volume":"112","author":"Wong","year":"2005","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD009510.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.ajo.2007.07.015","article-title":"Retinal vein occlusions and mortality: the Beijing Eye Study","volume":"144","author":"Xu","year":"2007","journal-title":"American Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD009510.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1167\/iovs.09-4453","article-title":"Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama study","volume":"51","author":"Yasuda","year":"2010","journal-title":"Investigative Ophthalmology and Visual Science"}],"updated-by":[{"DOI":"10.1002\/14651858.cd009510.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD009510.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T07:53:57Z","timestamp":1714895637000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD009510.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,31]]},"references-count":81,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009510.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD009510.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,31]]}}}